Lantheus Holdings Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $62.495
- Today's High:
- $65.03
- Open Price:
- $64.73
- 52W Low:
- $47.46
- 52W High:
- $100.851
- Prev. Close:
- $65.35
- Volume:
- 1046882
Company Statistics
- Market Cap.:
- $4.47 billion
- Book Value:
- 8.078
- Revenue TTM:
- $1.12 billion
- Operating Margin TTM:
- 14.04%
- Gross Profit TTM:
- $581.70 million
- Profit Margin:
- 2.97%
- Return on Assets TTM:
- 8.4%
- Return on Equity TTM:
- 5.96%
Company Profile
Lantheus Holdings Inc had its IPO on 2015-06-25 under the ticker symbol LNTH.
The company operates in the Healthcare sector and Drug Manufacturers-Specialty & Generic industry. Lantheus Holdings Inc has a staff strength of 698 employees.
Stock update
Shares of Lantheus Holdings Inc opened at $64.73 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $62.5 - $65.03, and closed at $64.1.
This is a -1.91% slip from the previous day's closing price.
A total volume of 1,046,882 shares were traded at the close of the day’s session.
In the last one week, shares of Lantheus Holdings Inc have slipped by -4.75%.
Lantheus Holdings Inc's Key Ratios
Lantheus Holdings Inc has a market cap of $4.47 billion, indicating a price to book ratio of 5.8686 and a price to sales ratio of 4.5183.
In the last 12-months Lantheus Holdings Inc’s revenue was $1.12 billion with a gross profit of $581.70 million and an EBITDA of $212.37 million. The EBITDA ratio measures Lantheus Holdings Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Lantheus Holdings Inc’s operating margin was 14.04% while its return on assets stood at 8.4% with a return of equity of 5.96%.
In Q2, Lantheus Holdings Inc’s quarterly earnings growth was a positive 118% while revenue growth was a positive 43.8%.
Lantheus Holdings Inc’s PE and PEG Ratio
- Forward PE
- 31.4465
- Trailing PE
- 136.1458
- PEG
- 0.61
Its diluted EPS in the last 12-months stands at $0.48 per share while it has a forward price to earnings multiple of 31.4465 and a PEG multiple of 0.61. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Lantheus Holdings Inc’s profitability.
Lantheus Holdings Inc stock is trading at a EV to sales ratio of 4.5791 and a EV to EBITDA ratio of 16.9644. Its price to sales ratio in the trailing 12-months stood at 4.5183.
Lantheus Holdings Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $1.34 billion
- Total Liabilities
- $154.04 million
- Operating Cash Flow
- $-20697000.00
- Capital Expenditure
- $10.70 million
- Dividend Payout Ratio
- 0%
Lantheus Holdings Inc ended 2024 with $1.34 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.34 billion while shareholder equity stood at $552.65 million.
Lantheus Holdings Inc ended 2024 with $0 in deferred long-term liabilities, $154.04 million in other current liabilities, 698000.00 in common stock, $-101834000.00 in retained earnings and $61.19 million in goodwill. Its cash balance stood at $414.08 million and cash and short-term investments were $414.08 million. The company’s total short-term debt was $384,000 while long-term debt stood at $559.24 million.
Lantheus Holdings Inc’s total current assets stands at $752.22 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $256.28 million compared to accounts payable of $38.86 million and inventory worth $51.80 million.
In 2024, Lantheus Holdings Inc's operating cash flow was $-20697000.00 while its capital expenditure stood at $10.70 million.
Comparatively, Lantheus Holdings Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $64.1
- 52-Week High
- $100.851
- 52-Week Low
- $47.46
- Analyst Target Price
- $121.5
Lantheus Holdings Inc stock is currently trading at $64.1 per share. It touched a 52-week high of $100.851 and a 52-week low of $100.851. Analysts tracking the stock have a 12-month average target price of $121.5.
Its 50-day moving average was $75.36 and 200-day moving average was $73.77 The short ratio stood at 4.37 indicating a short percent outstanding of 0%.
Around 280.5% of the company’s stock are held by insiders while 10088.2% are held by institutions.
Frequently Asked Questions About Lantheus Holdings Inc
Similar Industry Stocks (Drug Manufacturers-Specialty & Generic)
Most Active
Top Gainers
Top Losers
About
Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine; Xenon-133 to assess pulmonary function; Neurolite to identify the area within the brain where blood flow has been blocked or reduced due to stroke; and Cardiolite, an injectable Tc-99m-labeled imaging agent. The company also offers AZEDRA, a radiotherapeutic therapy; Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and PYLARIFY for visualization of lymph nodes, bone, and soft tissue metastases to determine the presence or absence of recurrent and/or metastatic prostate cancer. It also develops flurpiridaz to assess blood flow to the heart; 1095, a PSMA-targeted iodine-131 labeled small molecule; PNT2002 for pre-chemotherapy patients; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; and PYLARIFY AI, an AI-based medical device software to perform standardized quantitative assessment of PSMA PET/CT images in prostate cancer. The company serves hospitals, independent diagnostic testing facilities, government facilities, integrated delivery networks, radiopharmacies, clinics, distirbutors, and group practices. It has strategic partnerships with NanoMab Technology Limited; Bausch Health Companies, Inc.; GE Healthcare Limited; and FUJIFILM. The company was founded in 1956 and is based in Bedford, Massachusetts.